Company intelligence / Profile preview
Versatope Therapeutics
Lowell, Massachusetts, United Statesversatope.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Versatope Therapeutics has demonstrated robust and durable cross-strain immunity in preclinical models with its universal influenza vaccine candidate. The company’s proprietary nano-vesicle platform shows versatility in targeting infectious diseases, cancer, coronaviruses, and allergies. The lead program is preparing for IND-enabling studies; no clinical trial results are yet available.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Recombinant extracellular transport vesicles (nano-vesicles/exosomes)Targeted RNA therapeuticsGenetically engineered probiotic vesicles
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
JLabsMassChallengeCornell University
Beyond the preview
Go deeper on Versatope Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Versatope Therapeutics.